Hyper Lab Blog
Beyond new drug development, sharing pharmaceutical and biotech news.
Most Recent

AI
The Evolution of AI Drug Discovery: Past, Present, and Future
Here’s why AI drug development is gaining attention, along with its past, present, and future at a glance
히츠 하이퍼랩 팀2025.03.21

AI
Hyper Screening X : World's Largest Molecular Library Powers the Future of Drug Development
Hyper Screening X utilizes RxnFlow to efficiently explore a 7-trillion-compound ultra-large library, identifying innovative drug candidates with low binding energy and over 60% synthetic feasibility.
Jaechang Lim, CTO2025.03.14

AI
The First AI-Physics Hybrid Docking: Advancing Drug Development Accuracy
In this article, we introduce the development background and outstanding performance of PIGNet, which overcomes the limitations of traditional molecular docking by integrating deep learning with physical laws.
Jaechang Lim, CTO2025.03.07

AI
ICLR 2025 Preview
Introducing the AI-driven drug discovery research unveiled at ICLR 2025: RxnFlow, DynamicFlow, and NEXT-MOL
Sunghan Bae, AI Researcher2025.02.17

AI
DeepSeek AI : A Breakthrough in AI Efficiency
DeepSeek AI has recently emerged as a major player in the AI industry, offering cutting-edge models with high performance at a significantly lower cost.
Hyunkyu Lee, AI Researcher2025.02.11

Drug Discovery
FDA Approved Drugs in January 2025 – Latest Breakthroughs
In January 2025, the U.S. Food and Drug Administration (FDA) approved several new drugs targeting various diseases.
HITS Hyper Lab TEAM2025.02.06

AI
Beyond LLMs: The Future of AI-Driven Protein Design
Big Tech's AI race is shifting from LLMs to protein design. Google DeepMind and OpenAI are taking different approaches, sparking anticipation for breakthroughs in life sciences and drug development.
Junhyeok Jeon, AI Researcher2025.02.05

Drug Discovery
AI Drug Discovery case study - EP1. Hyper Screening
We introduce a case study on utilizing Hyper Screening to develop a MARK4 inhibitor drug. This article covers the process from identifying initial hit compounds to analyzing experimental results.
Heejin Jung, R&D Strategy Team Lead2025.01.20

Drug Discovery
AI Drug Discovery with Hyper Lab: “9x Higher Screening Success Rate, 90% Faster Development Time”
AI Drug Discovery: From 5 Years to Just 3 Months—Discovering a 100nM Active Compound with Hyper Lab
Jaechang Lim, CTO2025.01.14

Drug Discovery
2024 FDA Approved Drug Roundup
Oncology, immunology, and metabolic diseases dominated the top 50 FDA-approved drugs in 2024, with innovative treatments like Lazertinib and diverse drug types.
Seungmin Jung, R&D Starategy Team Researcher2025.01.06